Key Highlights:

  • Tango Therapeutics shares fell 15.11% to $23.71 on October 23, 2026, the first day of the ESMO Congress.
  • Earlier vopimetostat plus daraxonrasib data showed a 92% objective response rate and a 90% six-month progression-free survival rate.
  • Cash, equivalents and marketable securities totaled $1.0 billion on June 30, 2026.
  • The second-quarter net loss was $55.3 million, or $0.37 per share.
  • A randomized Phase 3 trial design in front-line pancreatic cancer is planned to be finalized in the second half of 2026.

ESMO Week: Why Is Tango Therapeutics Stock Down 15% on October 23, 2026?

Tango Therapeutics (NASDAQ:TNGX) shares fell 15.11% to $23.71 on Friday, October 23, 2026. The company has not announced a catalyst for the move.

The session coincided with the opening of the ESMO Congress in Madrid, which runs October 23 to 27, 2026. Tango said in August that it would present Phase 1/2 data for vopimetostat combined with RAS(ON) inhibitors at the meeting, so the decline may reflect positioning around that event.

Tango develops precision oncology medicines for cancers with MTAP deletions, and vopimetostat is its main program.

Vopimetostat Data: What Has Tango Already Shown in Pancreatic Cancer?

In its second-quarter release on August 11, 2026, the company reported a 92% objective response rate and a 90% six-month progression-free survival rate for vopimetostat plus daraxonrasib in MTAP-deleted, RAS-mutant pancreatic cancer. The release described the combination as generally well tolerated and did not state the patient count.

An earlier update on June 8, 2026 covered 12 patients with at least 14 weeks of follow-up, of whom 11 responded. Shares rose as much as 49% in morning trading that day, according to a news report.

Two patients on the higher vopimetostat dose had severe side effects, and investigators did not test a higher dose. The ESMO presentation is the first chance to see the full dataset.

Financial Position: How Much Cash Does Tango Hold?

Tango ended June 30, 2026 with $1.0 billion in cash, cash equivalents and marketable securities. The company said the balance is expected to be sufficient for its current operating plan, without giving a specific runway.

The second-quarter net loss was $55.3 million, or $0.37 per share, up from $38.9 million, or $0.35 per share, a year earlier. Collaboration revenue was zero, compared with $3.2 million.

At $23.71, the shares are about 14.3% below the $27.67 close of August 10, 2026 (calculated), and the 52-week range reported in August was $6.25 to $34.39.

Pipeline Timeline: What Else Is Expected in the Second Half of 2026?

Tango plans to start a Phase 3 trial of the combination later in 2026, after finalizing a randomized design in front-line pancreatic cancer. Additional second-half milestones include Phase 1/2 data for vopimetostat as lung cancer monotherapy and first data for TNG456 in glioblastoma and other cancers.

The company also plans to start a Phase 1/2 study combining vopimetostat with an inhibitor from Erasca (NASDAQ:ERAS). The pancreatic program depends in part on daraxonrasib, a drug developed by Revolution Medicines (NASDAQ:RVMD) that nearly doubled survival in a Phase 3 study, according to a news report.

What to Watch Next: Will the ESMO Presentation Confirm the Early Response Rates?

The takeaway from October 23, 2026 is that the shares fell sharply on the first day of the congress, with no company-announced reason. The next dated event is the ESMO meeting through October 27, 2026, followed by third-quarter results, for which the company has not announced a date. The key figures to follow are the response rate, progression-free survival and safety at the higher dose.

Shares fell 15.11% to $23.71 on the first day of the ESMO Congress. The company has not announced a catalyst.

The company reported a 92% objective response rate and a 90% six-month progression-free survival rate with daraxonrasib.

It held $1.0 billion in cash, equivalents and marketable securities on June 30, 2026.